Bioventus Inc. Class A Common Stock (BVS) Stock Price, Quote & AI Analysis

Live BVS stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Bioventus Inc. Class A Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Bioventus Inc. Class A Common Stock (BVS), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

BVS
Bioventus Inc. Class A Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
8.100000
High
8.400000
Low
8.080000
Volume
315,175
VWAP
-
Market Cap
$542,509,463.70
52W Range
$5.81 - $11.25
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 9, 2026 Q4
After Hours
EPS Estimate: $0.2172
Revenue Estimate: $157,122,336.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Bioventus Inc. Class A Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Bioventus Inc. Class A Common Stock Overview

Company information

Company Overview

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Company Details
Market Cap
$679.90M
Shares Outstanding
82,763,220
Weighted Shares Outstanding
66,976,477
CEO
Robert Claypoole
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703
Employees
950
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Bioventus Inc. Class A Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...